No Data
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
Viking Therapeutics Is Winning New Fans - and Not for Its Weigh-loss Pill
Express News | Viking Therapeutics Shares Rise 4.6% Premarket After Co Presents Detailed Mid-Stage Data for Experimental Liver Disease Drug
Viking Phase 2b Study of NASH Candidate Hits Primary Endpoint
Express News | Viking Therapeutics Presents Results From Phase 2B Voyage Study of Vk2809 in Biopsy-Confirmed Nash/Mash at the 75TH Liver Meeting® 2024
Viking Therapeutics Presents Results From Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024
No Data
No Data
